Restricted accessReview articleFirst published online 2005-09
Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders
A systematic review of randomized controlled trials of the use of atypical antipsychotics and selective serotonin reuptake inhibitors in the treatment of behavioural problems associated with pervasive developmental disorders is reported. A search through both published and unpublished literature, including contacting drug companies and known experts in the field was undertaken. Six trials met the criteria for inclusion in the review. They largely suffer from methodological weaknesses; only two trials had satisfactory methodological quality. The heterogeneity in outcome measurements prevented from conducting a meta-analysis. There is yet no coherent body of data concerning the effects of these medications across all sub-classifications of pervasive developmental disorders, across all age categories, and concerning their medium- and long-term effects, and their effects on quality of life. Atypical antipsychotics and selective serotonin reuptake inhibitors may be of benefit for behavioural problems associated with pervasive developmental disorders. Risperidone has been the best studied among these medications. Atypical antipsychotics appear to have a low risk of extrapyramidal symptoms during short-term treatment. The reviewed trials cannot provide data on the use of selective serotonin reuptake inhibitors in the treatment of children with pervasive developmental disorders. No firm conclusions for clinical practice can be drawn. Larger, well-conducted randomized controlled trials with long-term follow-up are needed.
Alderson P, Green S, Higgins J P T (eds) (2004) Cochrane Reviewers’ Handbook 4.2.2 (updated March 2004). In The Cochrane Library, Issue 1,. Chichester, John Wiley & Sons, Ltd
2.
Alderson P, Green S, Higgins J P T (eds) (2004) Assessment of study quality. Cochrane Reviewers’ Handbook 4.2.2 (updated March 2004), Section 6. In The Cochrane Library, Issue 1, 2004. Chichester, John Wiley & Sons, Ltd
3.
Aman M (2001) ‘Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms’. Ohio State University, Columbus, Ohio, US. Estimated completion date: February 2001
4.
Aman M G (1994) Instruments for assessing treatment effects in developmentally disabled populations. Assessment in Rehabilitation and Exceptionality1: 1-20
5.
Aman M G (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. The Am J Psychiatry159(8): 1337-1346
6.
Aman M G, Langworthy K S (2000) Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord30(5): 451-459
7.
Aman M G, van Bourgondien M E, Wolford P L, Sarphare G (1995) Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry34: 1672-1681
8.
American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, DSM-III-TR (text revision). American Psychiatric Association, Washington, DC
9.
American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edn, DSM-IV. American Psychiatric Association, Washington, DC
10.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, DSM-IV-TR (text revision). American Psychiatric Association, Washington, DC
11.
Anderson G M, Freedman D X, Cohen D J, Volkmar F R, Hoder E L, McPhedran P, Minderaa R B, Hansen C R, Young J G (1987) Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry28: 885-900
12.
Arnold E L, Aman M G, Martin A (2000) Assessment in multisite randomised clinical trial of patients with autistic disorder: the Autism RUPP Network. J Autism Dev Disord30(2): 99-110
13.
Bailey A, Bolton P, Butler L (1993) Prevalence of the fragile X anomaly amongst autistic twins and singletons. J Child Psychol Psychiatry34: 673-688
14.
Barnard L, Young A H, Pearson J, Geddes J, O’Brien G (2002) A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol16(1): 93-101
15.
Bolton P F, Griffiths P D (1997) Association of tuberous sclerosis of temporal lobes with autism and atypical autism (comments). Lancet349: 392-395
16.
British Medical Association, Royal Pharmaceutical Society of Great Britain (2004) Central Nervous System. Drugs used in psychoses and related disorders. Antipsychotic drugs. Atypical antipsychotics. British National Formulary47(March): 179-183
17.
Broadstock M, Doughty C (2003) The effectiveness of pharmacological therapies for young people and adults with Autism Spectrum Disorder (ASD). New Zealand Health Technology Assessment (NZHTA) Report 2003 6(1)
18.
Buchsbaum M S, Hollander E, Haznedar M M (2001) Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol4: 119-125
19.
Buck O D (1995) Sertraline for reduction of violent behaviour [Letter]. Am J Psychiatry152: 953
20.
Carter A S, Volkmar F R, Sparrow S S, et al. (1998) The Vineland Adaptive Behaviour Scales: supplementary norms for individuals with autism. J Autism Dev Disord28: 287-302
21.
Chen N C, Bedair H S, McKay B, Bowers M B Jr, Mazure C (2001) Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry62: 479-480
22.
Cohen S A (1998) Risperidone for aggression and self-injurious behaviour in adults with mental retardation. J Autism Dev Disord28: 229-233
23.
Cook E H, Leventhal B L (1996) The serotonin system in autism. Curr Opin Pediatr8: 348-354
24.
Cook E H Jr, Rowlet R, Jaselskis C, Leventhal B L (1992) Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry31: 739-745
25.
Crombie I K (1996) The Pocket Guide to Critical Appraisal. BMJ Publishing Group (London)
26.
Damore J, Stine J, Brody L (1998) Medication-induced hypomania in Asperger’s disorder [Letter]. J Am Acad Child Adolesc Psychiatry37: 248-249
27.
Dartnall N A (1999) Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord29: 87-91
28.
Davanzo P A, Belin T R, Widawski M H, King B H (1998) Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard102: 427-437
29.
DeLong G R. (1998) Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol4: 551-562
30.
DeLong G R (2002) Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol44: 652-659
31.
Diler R S (2002) An open-label trial of risperidone in children with autism. Curr Therap Research63(1): 91-102
32.
Dollfus S, Petit M, Menard J F, Lesieur P (1992) Amisulpride versus bromocriptine in infantile autism: A controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. J Autism Dev Disord22(1): 48-60
33.
Fatemi S H (1998) Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord28: 303-307
34.
Ghaziuddin M, Tsai L, Ghaziuddin N (1991) Fluoxetine in autism with depression [Letter]. J Am Acad Child Adolesc Psychiatry30: 508-509
35.
Gillberg C (1991) Outcome in autism and autistic like-conditions. J Am Acad Child Adolesc Psychiatry3: 375-382
36.
Greenhalgh T (1997) How to read a paper: The basics of evidence based medicine. BMJ Publishing Group
37.
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, US Dept of Health, Education, and Welfare, Washington, DC, Publication no. (ADM) 76-338
38.
Harvey R J, Cooray S E (1995) The effective treatment of severe repetitive behaviour with Fluvoxamine in a 20 year old autistic female. Internat Clin Psychopharmacol10: 201-203
39.
Hellings J A, Kelley L A, Gabrielli W F, Kilgore E, Shah P (1996) Sertra-line response in adults with mental retardation and autistic disorder. J Clin Psychiatry, 57: 333-336
40.
Hellings J A, Zarcone J R (2001) Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol11(3): 229-238
41.
Hellings J A, Zarcone J RA crossover study of risperidone in children, adolescents and adults with mental retardation. Forthcoming
42.
Hollander ERandomized study of fluoxetine in children and adolescents with autism. Ongoing study. Mount Sinai Medical Center, US
43.
Hollander EFluoxetine versus placebo in adult autistic disorder. Ongoing study. Estimated completion date: August 2004 Mount Sinai School of Medicine, New York, US
44.
Hollander E (2000) Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol15(2): 132-135
45.
Horrigan J P (1997) Risperidone and explosive aggressive autism. J Autism Dev Disord27: 313-323
46.
Hoshino Y, Tachibana J R, Watanabe M, Murata S, Yokoyama F, Kaneko M, Yashima Y, Kumoshiro H (1984) Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Japan J Psychiatry Neurol26: 937-945
47.
Hughes D M (2002) Risperidone in children and adolescents with autistic disorder and aggressive behaviour. Br J Dev Disabil48(Part 2, No. 95): 113-122
48.
Janicak P G, Davis J M, Preskorn S H, Ayd F J Jr (2001) Principles and Practice of Psychopharmacotherapy. Lippincott Williams & Wilkins, Philadelphia, PA
49.
Kemner C, van Engeland H, Tuynman-Qua H (2000) An open-label study of olanzapine in children with PDD. Schizophr Res41(1): 194
50.
King, B H (2000) Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord30(5): 439-445
51.
Koshes R J (1997) Use of fluoxetine for obsessive-compulsive behavior in adults with autism. Am J Psychiatry154(4): 578
52.
Krug D A, Arick J, Almond P (1980) Behaviour checklist for identifying severely handicapped individuals with high levels of autistic behaviour. J Child Psychol Psychiatry21: 221-229
53.
Llorca P M, Chereau I, Bayle F J (2002) Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry17: 129-138
54.
Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview - Revised: a revised version of a diagnostic interview for caregivers of individuals with possible PDDs. J Autism Dev Disord24: 659-685
55.
Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schopler E (1989) Autism Diagnostic Observation Schedule (ADOS). J Autism Dev Disord19(2): 185-212
56.
Malone R P (2005) A controlled study of olanzapine in children with autism. Ongoing study. Estimated completion date: September 2005. Eastern Pennsylvania Psychiatric Institute, Philadelphia, Pennsylvania, US.
57.
Malone R P, Cater J, Sheikh R M, Choudhury M S, Delaney M A (2001) Olanzapine versus Haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry40(8): 887-894
58.
Malone R P (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry41(2): 140-147
59.
Martin A (2003) Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord33(1): 77-85
60.
Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol9: 99-107
61.
Martin A, Scahill L, Klin A, Volkmar F R (1999) Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry3: 923-931
62.
Masi G (2001) Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol16: 395-400
63.
Masi G, Cosenza A (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry40(10): 1206-1214
64.
McBride P A, Anderson G M, Hertzig M E, Sweeney J A, Kream J, Cohen D J, Mann J J (1989) Serotonergic responsivity in male young adults with autistic disorder: results of a pilot study. Arch Gen Psychiatry46: 213-221
65.
McCracken J T (no date) Citalopram Treatment in Children with Autism Spectrum Disorders and High Levels of Repetitive Behavior. Ongoing study. Estimated completion date: March 2007. UCLA Neuropsychiatric Institute, Los Angeles, California, US.
66.
McCracken J T, McGough J, Shah B, Cronin P, Hong D, Aman M G, Arnold L Eet al. (2002) Risperidone in children with autism and serious behavioral problems: research units on pediatric psychopharmacology autism network. New Engl J Med347(5): 314-321
67.
McDougle C J (1997) Psychopharmacology. In Cohen D J, Volkmar F R (eds), Handbook of Autism and Pervasive Developmental Disorders, 2nd edn, publisher and place of pub
68.
McDougle C J (2002) Current and emerging therapeutics of autistic disorder and related pervasive developmental disorders. In Davis K Let al. (eds), Neuropsychopharmacology: The Fifth Generation of Progress. An official publication of the American College of Neuropsychopharmacology
69.
McDougle C J, Brodkin E S, Naylor S T, Carlson D C, Cohen D J, Price L H (1998) Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol18: 62-66
70.
McDougle C J, Holmes J P, Bronson M R (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry36: 685-693
71.
McDougle C J, Holmes J P, Carlson D C, Pelton G H, Cohen D J, Price L H (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry55: 633-641
72.
McDougle C J, Kem D L, Posey D J (2002) Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry41(8): 921-927
73.
McDougle C J, Kresh L E, Posey D J (2000) Repetitive thoughts and behaviour in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord30(5): 427-435
74.
McDougle C J, Naylor S T, Cohen D J, Aghajanian G K, Heninger G R, Price L H (1996) Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry53: 993-1000
75.
McDougle C J, Naylor S T, Cohen D J, Volkmar F R, Heninger G R, Price L H (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder’. Arch Gen Psychiatry53: 1001-1008
76.
McDougle C J, Price L H, Goodman W K (1990) Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case-report. J Autism Dev Disord20: 537-543
77.
McDougle C J, unpublished data. In Posey D J, McDougle C J (2000) The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry8(2): 45-63
78.
Mehlinger R, Scheftner W A, Poznanski E (1990) Fluoxetine and autism [Letter]. J Am Acad Child Adolesc Psychiatry29: 985
79.
Minshew N J, Meyer J A, Dunn M (2003) Autism spectrum disorders. In Segalowitz S J, Rapin I (eds), Handbook of Neuropsychology, 2nd edn, Vol. 8, Part II: 863-896
80.
Namerow L B (2003) Use of citalopram in pervasive developmental disorders. Dev Behav Pediatr24(2): 104-108
81.
Nicolson R (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry37(4): 372-376
82.
Ozbayrak K R (1997) Sertraline in PDD [Letter]. J Am Acad Child Adolesc Psychiatry36: 7-8
83.
Peral M (1999) Fluoxetine in children with autism. J Am Acad Child Adolesc Psychiatry38(12) (Letters to the Editor): 1472-1473
84.
Perry R (1997) Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. J Child Adolesc Psychopharmacol7(3): 167-179
85.
Pertejo A (2000) Estudio abierto con fluoxetina en nin'os con autismo (An open study of fluoxetine in children with autism). Actas Espanolas de Psiquiatria28(6): 353-356
86.
Posey D J, Litwiller M, Koburn A, McDougle C J (1999) Paroxetine in autism. J Am Acad Child Adolesc Psychiatry38(2) (Letters to the Editor): 111-112
87.
Posey D J, McDougle C J (2000) The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry8(2): 45-63
88.
Posey D J, McDougle C J (2003) Use of atypical antipsychotics in autism. In Hollander E (ed.), Autism Spectrum Disorders
89.
Posey D J, Walsh K H, Wilson G A, McDougle C J (1999) Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol9: 273-276
90.
Potenza M N, McDougle C J (1997) The role of serotonin in autism-spectrum disorders. CNS Spectrums2: 25-42
91.
Potenza M N (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: a prospective open-label study. J Clin Psychopharmacol19: 37-44
92.
Scahill LRisperidone and behavioral therapy in treatment of children and adolescents with autistic disorder. Ongoing study. Estimated completion date: March 2006. Yale University, New Haven, CN, US
93.
Schopler E, Reichler R, Renner B R (1988) Child Autism Rating Scale. Western Psychological Services, Los Angeles, CA
94.
Schreier H A (1998) Risperidone for young children with mood disorders and aggressive behaviour. J Child Adolesc Psychopharmacol8(1): 45-59
95.
Simeon J, Milin R (2002) A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry26(2): 267-275
96.
Snead R W, Boon F, Presberg J (1994) Paroxetine for self-injurious behaviour [Letter]. J Am Acad Child Adolesc Psychiatry33: 909-910
97.
Sokolski K N (2004) Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series. J Child Adolesc Psychopharmacol14(1): 143-147
98.
Steingard R J, Zimnitzky B, DeMaso D R, Bauman M L, Bucci J P (1997) Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol7: 9-15
99.
Stavrakaki C (2004) Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci29(1): 57-60
100.
Stigler K A, Posey D J, McDougle C (2002) Recent advances in the pharmacotherapy of autism. Expert Rev Neurotherapeutics2(4): 499-510
101.
Tanguay P E (2000) Pervasive developmental disorders: a 10-year review. J Am Acad Child Adolesc Psychiatry39(9): 1079-1094
102.
Todd R D (1991) Fluoxetine in autism [Letter]. Am J Psychiatry148: 1089
103.
Vegso S J (1995) A double-blind, placebo-controlled study of fluvoxamine in treating the symptoms of autism. The Cochrane Library, Dissertation: MAI 34/02, p. 711, Apr 1996
104.
Vercellino (2001) Open-label risperidone treatment of 6 children and adolescents with autismCanad J Psychiatry46(6) (Letters to the Editor): 559-560
105.
Volkmar F R, Cohen D J (1991) Comorbid association of autism and schizophrenia. Am J Psychiatry148: 1705-1707
106.
Wheeler D M, Hazell P, Silove N, Williams K (2004) Selective serotonin reuptake inhibitors for the treatment of autism spectrum disorders (Protocol for a Cochrane Review). In The Cochrane Library, Issue 1, 2004. John Wiley & Sons, Ltd, Chichester
107.
Wing L (1999) Diagnostic Interview for Social and Communication Disorders. 10th edn.The National Autistic Society, London
108.
World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva
109.
Zarcone J R, Hellings J A (2001) Effects of risperidone on aberrant behaviour of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard106(6): 525-538
